CurrentHealthcarePortfolioVenture Incubator


inositec Logo

Inositec AG is a pre-clinical stage biotech spin-off from ETH Zurich developing innovative new drugs from its proprietary platform of inositol phosphate analogs with tunable properties (InosituneTM).  Inositec’s lead product is an inhibitor of Clostridium difficile toxins that aims to offer a highly differentiated, non-antibiotic oral treatment option for C. difficile infection patients. The second product is a vascular calcification inhibitor for chronic kidney disease patients.

Learn more on